Non-high-density lipoprotein cholesterol in patients with metabolic syndrome

Jian Huang, Roy Parish, Ishak Mansi, Herbert Yu, Estela M. Kennen, Terry Davis, Donna Carden

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Metabolic syndrome (MS) represents a cluster of cardiovascular risk factors that includes hypertriglyceridemia. Although low-density lipoprotein (LDL) cholesterol is the critical therapeutic target in patients with coronary artery disease, LDL cannot be calculated in those with excessive hypertriglyceridemia. Non-high-density lipoprotein (HDL) does not require LDL for calculation and may be an alternative therapeutic target in MS. The purpose of this study was to determine non-HDL cholesterol in relation to other lipid components and comorbidities in MS patients. Methods: A cross-sectional chart review on 928 public hospital patients was performed. Results: Metabolic syndrome was present in 53% of all patients. Among those with MS, 87% had triglyceride level of greater than 150 mg/dL, 85% had low HDL, 71% had LDL of greater than 100 mg/dL, and 74% had non-HDL of greater than 130 mg/dL. The level of non-HDL cholesterol, but not total cholesterol or LDL cholesterol, was significantly higher (P <; 0.05) and less at goal (P < 0.0001) in patients with MS. Diagnoses of coronary artery disease, hypertension, obesity, dyslipide-mia, and diabetes were significantly more prevalent in MS patients (P < 0.0001). Conclusion: Compared with those without MS, non-HDL level was significantly higher and undertargeted in patients with MS, in parallel with significantly higher prevalence of comorbidities.

Original languageEnglish (US)
Pages (from-to)931-936
Number of pages6
JournalJournal of Investigative Medicine
Volume56
Issue number7
DOIs
StatePublished - Jan 1 2008

Fingerprint

LDL Lipoproteins
Lipoproteins
LDL Cholesterol
HDL Lipoproteins
Medical problems
Triglycerides
Hypertriglyceridemia
Cholesterol
Lipids
Comorbidity
Coronary Artery Disease
lipoprotein cholesterol
Public Hospitals
Obesity
Hypertension
Therapeutics

Keywords

  • Cardiovascular risk
  • Dyslipidemia
  • Metabolic syndrome
  • Non-HDL cholesterol

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Non-high-density lipoprotein cholesterol in patients with metabolic syndrome. / Huang, Jian; Parish, Roy; Mansi, Ishak; Yu, Herbert; Kennen, Estela M.; Davis, Terry; Carden, Donna.

In: Journal of Investigative Medicine, Vol. 56, No. 7, 01.01.2008, p. 931-936.

Research output: Contribution to journalArticle

Huang, Jian ; Parish, Roy ; Mansi, Ishak ; Yu, Herbert ; Kennen, Estela M. ; Davis, Terry ; Carden, Donna. / Non-high-density lipoprotein cholesterol in patients with metabolic syndrome. In: Journal of Investigative Medicine. 2008 ; Vol. 56, No. 7. pp. 931-936.
@article{9eb799ab41c64a5286f78500e2ae1bcc,
title = "Non-high-density lipoprotein cholesterol in patients with metabolic syndrome",
abstract = "Background: Metabolic syndrome (MS) represents a cluster of cardiovascular risk factors that includes hypertriglyceridemia. Although low-density lipoprotein (LDL) cholesterol is the critical therapeutic target in patients with coronary artery disease, LDL cannot be calculated in those with excessive hypertriglyceridemia. Non-high-density lipoprotein (HDL) does not require LDL for calculation and may be an alternative therapeutic target in MS. The purpose of this study was to determine non-HDL cholesterol in relation to other lipid components and comorbidities in MS patients. Methods: A cross-sectional chart review on 928 public hospital patients was performed. Results: Metabolic syndrome was present in 53{\%} of all patients. Among those with MS, 87{\%} had triglyceride level of greater than 150 mg/dL, 85{\%} had low HDL, 71{\%} had LDL of greater than 100 mg/dL, and 74{\%} had non-HDL of greater than 130 mg/dL. The level of non-HDL cholesterol, but not total cholesterol or LDL cholesterol, was significantly higher (P <; 0.05) and less at goal (P < 0.0001) in patients with MS. Diagnoses of coronary artery disease, hypertension, obesity, dyslipide-mia, and diabetes were significantly more prevalent in MS patients (P < 0.0001). Conclusion: Compared with those without MS, non-HDL level was significantly higher and undertargeted in patients with MS, in parallel with significantly higher prevalence of comorbidities.",
keywords = "Cardiovascular risk, Dyslipidemia, Metabolic syndrome, Non-HDL cholesterol",
author = "Jian Huang and Roy Parish and Ishak Mansi and Herbert Yu and Kennen, {Estela M.} and Terry Davis and Donna Carden",
year = "2008",
month = "1",
day = "1",
doi = "10.2310/JIM.0b013e318182080a",
language = "English (US)",
volume = "56",
pages = "931--936",
journal = "Journal of Investigative Medicine",
issn = "1081-5589",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Non-high-density lipoprotein cholesterol in patients with metabolic syndrome

AU - Huang, Jian

AU - Parish, Roy

AU - Mansi, Ishak

AU - Yu, Herbert

AU - Kennen, Estela M.

AU - Davis, Terry

AU - Carden, Donna

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Background: Metabolic syndrome (MS) represents a cluster of cardiovascular risk factors that includes hypertriglyceridemia. Although low-density lipoprotein (LDL) cholesterol is the critical therapeutic target in patients with coronary artery disease, LDL cannot be calculated in those with excessive hypertriglyceridemia. Non-high-density lipoprotein (HDL) does not require LDL for calculation and may be an alternative therapeutic target in MS. The purpose of this study was to determine non-HDL cholesterol in relation to other lipid components and comorbidities in MS patients. Methods: A cross-sectional chart review on 928 public hospital patients was performed. Results: Metabolic syndrome was present in 53% of all patients. Among those with MS, 87% had triglyceride level of greater than 150 mg/dL, 85% had low HDL, 71% had LDL of greater than 100 mg/dL, and 74% had non-HDL of greater than 130 mg/dL. The level of non-HDL cholesterol, but not total cholesterol or LDL cholesterol, was significantly higher (P <; 0.05) and less at goal (P < 0.0001) in patients with MS. Diagnoses of coronary artery disease, hypertension, obesity, dyslipide-mia, and diabetes were significantly more prevalent in MS patients (P < 0.0001). Conclusion: Compared with those without MS, non-HDL level was significantly higher and undertargeted in patients with MS, in parallel with significantly higher prevalence of comorbidities.

AB - Background: Metabolic syndrome (MS) represents a cluster of cardiovascular risk factors that includes hypertriglyceridemia. Although low-density lipoprotein (LDL) cholesterol is the critical therapeutic target in patients with coronary artery disease, LDL cannot be calculated in those with excessive hypertriglyceridemia. Non-high-density lipoprotein (HDL) does not require LDL for calculation and may be an alternative therapeutic target in MS. The purpose of this study was to determine non-HDL cholesterol in relation to other lipid components and comorbidities in MS patients. Methods: A cross-sectional chart review on 928 public hospital patients was performed. Results: Metabolic syndrome was present in 53% of all patients. Among those with MS, 87% had triglyceride level of greater than 150 mg/dL, 85% had low HDL, 71% had LDL of greater than 100 mg/dL, and 74% had non-HDL of greater than 130 mg/dL. The level of non-HDL cholesterol, but not total cholesterol or LDL cholesterol, was significantly higher (P <; 0.05) and less at goal (P < 0.0001) in patients with MS. Diagnoses of coronary artery disease, hypertension, obesity, dyslipide-mia, and diabetes were significantly more prevalent in MS patients (P < 0.0001). Conclusion: Compared with those without MS, non-HDL level was significantly higher and undertargeted in patients with MS, in parallel with significantly higher prevalence of comorbidities.

KW - Cardiovascular risk

KW - Dyslipidemia

KW - Metabolic syndrome

KW - Non-HDL cholesterol

UR - http://www.scopus.com/inward/record.url?scp=58149142897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149142897&partnerID=8YFLogxK

U2 - 10.2310/JIM.0b013e318182080a

DO - 10.2310/JIM.0b013e318182080a

M3 - Article

C2 - 18753978

AN - SCOPUS:58149142897

VL - 56

SP - 931

EP - 936

JO - Journal of Investigative Medicine

JF - Journal of Investigative Medicine

SN - 1081-5589

IS - 7

ER -